Pharmaceutical distribution is the most regulation-complex vertical in B2B. Thousands of products across 6 therapeutic families. Each product governed by GMP manufacturing, FMD/DSCSA serialisation, cold chain requirements (ambient, 2–8°C, −20°C, −70°C), batch traceability, and shelf-life management. 1,200 molecules × 4 dosage forms × 6 pack sizes × 3 temperature classes × 2 serialisation standards = 172,800 valid distribution combinations. A PDF cannot present this. A phone call cannot search it. A platform captures every formulary decision and compounds it into intelligence that predicts demand before the next CPHI.
Most pharma brands have invested heavily in DTC e-commerce, social media, and consumer marketing. But their wholesale operations — often 60–80% of total revenue — still look like they did a decade ago.
Email, phone, WhatsApp, CPHI Worldwide paper forms, and occasional fax. Each channel is a silo. No order generates behavioural data. No interaction enriches the buyer profile.
PDF lookbooks, Excel price lists, printed line sheets. Updated manually each season. Inconsistent across markets. No tracking of what buyers actually look at.
CRM knows who the buyer is. ERP knows what was ordered. But nobody knows what was browsed, compared, considered, and rejected. The most valuable data — buyer intent — is invisible.
A B2B shop for online orders. A CRM for contacts. An ERP for fulfilment. A BI tool for reports. Four systems, four data silos, zero connected intelligence.
No pre-visit intelligence on formulary status, biosimilar adoption, or P&T committee decisions. The rep carries printed SmPCs into a hospital pharmacy with zero structured context.
CPHI Worldwide generates hundreds of booth contacts. Business cards scanned, follow-up by email. Within 4 weeks, 80% of wholesaler leads have gone cold. Zero structured data remains.
Every time a pharma brand adds a new tool — a B2B webshop, a digital catalogue, a reporting dashboard — it creates another data silo. The webshop knows what buyers ordered online. The CRM knows what the sales rep discussed. The catalogue tool knows what PDFs were downloaded. But none of these systems talk to each other.
The result is not just inefficiency. It is structural data loss. Every manual process, every disconnected tool, every channel that operates independently destroys information that could have been used to make better decisions.
A platform is fundamentally different. It is not a collection of tools. It is one system where every interaction — from showroom presentation to portal restock — writes to the same buyer profile and reads from the same product data.
A platform does not just digitise your processes. It fundamentally changes how you understand your business.
A showroom visit captures 40+ data points. A portal session captures 28+. A field visit captures buyer context, product interest, and order patterns. Nothing is lost.
Sales Table, Sales App, B2B Portal, Digital Showroom, Remote — all read from and write to the same buyer profile. The sales rep knows what the buyer did on the portal. The portal knows what the rep showed in the showroom.
After three months, you see basic patterns. After six months, you predict seasonal behaviour. After twelve months, your data layer contains intelligence that no competitor can replicate.
Restock predictions, product trend forecasting, buyer segmentation, churn detection — all of these require structured data across all touchpoints. A platform provides this. Tools never can.
Pharma wholesale has characteristics that make the platform argument even stronger than in other industries.
A lip colour range with hundreds of variants across multiple formats is 144 SKUs from a single product. Multiply by 10 categories and 4 seasonal collections and you have complexity that Excel physically cannot handle — let alone analyse.
Pharma is sold visually. Textures, finishes, and true colour representation require digital surfaces — not static PDFs that lose quality and generate no data when opened.
New collections every quarter. Limited editions. Holiday specials. The speed at which pharma moves means every week without structured data capture is a week of lost intelligence.
In pharma, what buyers browse but do not buy is as valuable as what they order. product comparisons, collection dwell time, and abandoned selections reveal demand signals before they appear in sales reports.
Data compounds. The brands that start capturing structured buyer intelligence today will have 12 months of compounding data by next year. The brands that wait will start from zero.
This is not a cost-saving argument. It is a strategic advantage argument. The question is not whether your brand will need a platform. It is whether you will have the data when you do.
Start Building Your Data AdvantageTwo years from now, your competitor will have 24 months of structured buyer data — every product viewed, every comparison made, every restock predicted. If you start today, you will too. If you wait, you will be starting from zero while they compound their advantage every single day.
We spent three years adding tools. Each one solved one problem and created two new ones. Switching to a platform was the moment everything clicked.
The data advantage is real. After one year on the platform, we understand our buyers better than brands that have been in the market for a decade.
Tell us about your brand, your current B2B setup, and what you are looking to improve. We will show you exactly how FIRE works for your specific situation.
No generic demos. No slide decks. A real walkthrough with your products and your industry configuration.
Trusted by Hugo Boss, Drykorn, LVMH, Bugatti Shoes, Micro Mobility, Mercedes, Binelli Group and 100+ leading brands worldwide.
We replaced five disconnected tools with one platform. The first quarter alone gave us more buyer intelligence than the previous two years combined.
The data compounding effect is real. After six months, FIRE knows our buyers better than our most experienced sales rep.
Book a personalised demo — integrated with your ERP in 20–40 days.